News

Monday May 20, 2013

20 May 2013 – Press Release: Part 2 of NIAID-funded US clinical trial of anti-stap...

Brighton, UK – Clinical stage pharmaceutical company Destiny Pharma today announced the further progression of the Phase I US clinical trial of its lead drug XF-73 to Part 2 of […]